Conference Proceedings

Phase II COLET study: Atezolizumab (A) plus cobimetinib (C) plus paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).

Adam Brufsky, Sung-Bae Kim, Zanete Zvirbule, Luc Yves Dirix, Alexandru E Eniu, Francisco Carabantes, Yann Izarzugaza, Jeroen Mebis, Joohyuk Sohn, Matthew Wongchenko, Saibah Chohan, Reena Amin, VA McNally, David Miles, Sherene Loi

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2019


1013 Background: COLET showed that the addition of C (MEK1/2 inhibitor) to P resulted in an increased ORR (38%; Brufsky, SABCS 2017); IMpassion130 demonstrated clinical benefit with the combination of PD-L1 inhibitor A and nP as 1L tx for pts with mTNBC (Schmid, N Engl J Med, 2018). We investigated the efficacy and safety of A + C + P/nP in pts with mTNBC, as this combination may target multiple cancer immune escape mechanisms simultaneously. Methods: In the multi-stage, multi-cohort Phase II COLET study, pts with histologically confirmed mTNBC were randomized 1:1 to receive 1L tx with A 840 mg IV (d1, d15) + C 60 mg qd (d3-d23) + P 80 mg/m2 IV (d1, d8, d15; cohort 2) or + nP 100 mg/m2 (d1,..

View full abstract